A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

United States, California City of Hope Not yet **RECRUITING NOW** Duarte, California, United States, 91010 Principal Investigator: Vincent Chung, MD          United States, New York Weill Cornell Medicine Not yet **RECRUITING NOW** New York, New York, United States, 10021 Principal Investigator: Anna Pavlick, DO          United States, Texas MD Anderson Cancer Center Not yet **RECRUITING NOW** Houston, Texas, United States, 77030 Principal Investigator: Shubham Pant, MD          NEXT Oncology **RECRUITING NOW** San Antonio, Texas, United States, 78229 Principal Investigator: David Sommerhalder, MD          United States, Virginia NEXT Oncology **RECRUITING NOW** Fairfax, Virginia, United States, 22031 Principal Investigator: Alex Spira, MD, PhD         

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.